Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(169 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(79 produits)
- Syk(37 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1420 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ki11502
CAS :<p>Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.</p>Formule :C26H23N3O4SMasse moléculaire :473.54CEE321
CAS :<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formule :C18H16ClN5OCouleur et forme :SolidMasse moléculaire :353.806Hypothemycin
CAS :<p>Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.</p>Formule :C19H22O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :378.37FGFR1 inhibitor-16
CAS :<p>FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.</p>Formule :C16H9N5O3SCouleur et forme :SolidMasse moléculaire :351.339FAK-IN-3
<p>FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.</p>Formule :C28H28N6O4Couleur et forme :SolidMasse moléculaire :512.56FAK-IN-4
<p>FAK-IN-4 (Compound 7d) has anticancer activities that can induce cell apoptosis. FAK-IN-4 is potential inhibitor of FAK [1].</p>Formule :C20H22N4OCouleur et forme :SolidMasse moléculaire :334.41ALK-IN-31
CAS :<p>ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).</p>Formule :C30H33N5O2SCouleur et forme :SolidMasse moléculaire :527.68RGB-286638
CAS :<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Formule :C29H37Cl2N7O4Couleur et forme :SolidMasse moléculaire :618.55(S)-3-Hydroxy Midostaurin
CAS :<p>(S)-3-Hydroxy Midostaurin is a potent inhibitor of kinases(IC50 of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et)).</p>Formule :C35H30N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.64BTK-IN-15
<p>BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.</p>Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52FGFR4-IN-7
<p>FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.</p>Formule :C26H25Cl2N5O3Couleur et forme :SolidMasse moléculaire :526.41VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Formule :C24H18N6O2SCouleur et forme :SolidMasse moléculaire :454.5EGFR-IN-44
<p>EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.</p>Formule :C27H29ClN6O2SCouleur et forme :SolidMasse moléculaire :537.08DBMB
CAS :<p>DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.</p>Formule :C24H22N4OCouleur et forme :SolidMasse moléculaire :382.458HER2-IN-7
CAS :<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55BTK-IN-8
<p>BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).</p>Formule :C26H36N6O3Couleur et forme :SolidMasse moléculaire :480.6FLT3/ITD-IN-1
<p>FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.</p>Formule :C19H22N6O2Couleur et forme :SolidMasse moléculaire :366.42HSN748
CAS :<p>HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.</p>Formule :C27H24F3N7OCouleur et forme :SolidMasse moléculaire :519.521(Rac)-PT2399
CAS :<p>(Rac)-PT2399 is a potent and specific inhibitor of hypoxia-inducible factor 2a (HIF-2α)(IC50 of 0.01 μM).</p>Formule :C17H10F5NO4SCouleur et forme :SolidMasse moléculaire :419.32JBJ-02-112-05
CAS :<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54
